GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Operating Margin %

INBX (Inhibrx Biosciences) Operating Margin % : 0.00% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Inhibrx Biosciences's Operating Income for the three months ended in Mar. 2025 was $-42.90 Mil. Inhibrx Biosciences's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Inhibrx Biosciences's Operating Margin % for the quarter that ended in Mar. 2025 was 0.00%.

The historical rank and industry rank for Inhibrx Biosciences's Operating Margin % or its related term are showing as below:

INBX' s Operating Margin % Range Over the Past 10 Years
Min: -165724   Med: -12178.94   Max: -8864.18
Current: -150262


INBX's Operating Margin % is ranked worse than
98.78% of 980 companies
in the Biotechnology industry
Industry Median: -115.345 vs INBX: -150262.00

Inhibrx Biosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Inhibrx Biosciences's Operating Income for the three months ended in Mar. 2025 was $-42.90 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-300.52 Mil.


Inhibrx Biosciences Operating Margin % Historical Data

The historical data trend for Inhibrx Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Operating Margin % Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Operating Margin %
-8,864.18 -12,178.94 -165,724.00

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only - -160,898.00 - -49,928.00 -

Competitive Comparison of Inhibrx Biosciences's Operating Margin %

For the Biotechnology subindustry, Inhibrx Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx Biosciences's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Operating Margin % falls into.


;
;

Inhibrx Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Inhibrx Biosciences's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-331.448 / 0.2
=-165,724.00 %

Inhibrx Biosciences's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=-42.901 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibrx Biosciences  (NAS:INBX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Inhibrx Biosciences Operating Margin % Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.